Kalbe Farma Owned By Conglomerate Boenjamin Setiawan Divides Dividend Of Rp1.6 Trillion And Appoints UI Professor Rhenald Kasali As Independent Commissioner

JAKARTA - The pharmaceutical product producer owned by conglomerate Boenjamin Setiawan, PT Kalbe Farma Tbk, has received approval to distribute dividends from net income in 2021. The value is IDR 35 per share or equivalent to IDR 1.64 trillion.

This figure is equivalent to 51.53 percent of the 2021 net profit which reached Rp3.18 trillion.

Citing the minutes of Kalbe Farma's annual general meeting of shareholders (AGM), Monday, May 23, the company also set aside Rp31.84 billion from the net profit as a reserve fund.

In addition, Kalbe Farma also accepted the resignation of Lucky Surjadi Slamet from his position as an independent commissioner. As his successor, Kalbe Farma appointed a professor of Management Science, Faculty of Economics and Business, University of Indonesia Rhenald Kasali as an independent commissioner.

For information, throughout 2021, Kalbe Ffarma recorded a net sales increase of 13.6 percent to Rp26.26 trillion. From this note, the company's net profit rose 16.5 percent to IDR 3.18 trillion from the same period in 2020 of IDR 2.73 trillion.

Meanwhile, in the first three months of this year, the company's net sales have reached Rp7.01 trillion. This achievement is up 16.6 percent compared to the same period in 2021.

The net profit attributable to the owners of the KLBF parent entity reached IDR 835 billion in the first quarter of 2022. That figure was up 16.5 percent compared to IDR 716 billion in the same period last year.